Avalo CFO exercises RSUs, covers tax with shares

Avalo Therapeutics, Inc. Chief Financial Officer Christopher Ryan Sullivan reported routine equity compensation activity involving restricted stock units (RSUs).

Rhea-AI Filing Summary

Avalo Therapeutics, Inc. Chief Financial Officer Christopher Ryan Sullivan reported routine equity compensation activity involving restricted stock units (RSUs). On March 28, 2026, 24,200 RSUs converted on a one-for-one basis into 24,200 shares of common stock at a stated price of $0.00 per share.

Of the resulting common shares, 8,241 were disposed of at $13.89 per share to satisfy tax obligations, leaving 33,297 shares of common stock held directly after the transactions. A prior grant of 72,600 RSUs from August 13, 2024 vests in three equal installments on March 28, 2025, 2026, and 2027, subject to continued service.

Insider Trade Summary

24,200 shares exercised/converted

Exercise 3 txns

Insider Sullivan Christopher Ryan

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	24,200	$0.00	$0.00
Exercise	Common Stock	24,200	$0.00	$0.00
Exercise Price or Tax Liability	Common Stock	8,241	$13.89	$114K

Holdings After Transaction: Restricted Stock Units — 24,200 contracts (Direct); Common Stock — 33,297 shares (Direct)

Footnotes (2)

1. F1. Restricted stock units convert into common stock on a one-for-one basis.
2. F2. On August 13, 2024, the Reporting Person was granted 72,600 restricted stock units, vesting 1/3 on March 28, 2025, March 28, 2026, and March 28, 2027, subject to the Reporting Person's continued service on such vesting date.

Key Figures

RSUs converted: 24,200 units Tax-withholding shares: 8,241 shares Tax-withholding price: $13.89 per share +3 more

6 metrics

RSUs converted 24,200 units Restricted stock units converting one-for-one into common stock on March 28, 2026

Tax-withholding shares 8,241 shares Common shares delivered to cover tax liability at $13.89 per share

Tax-withholding price $13.89 per share Value used for shares disposed to satisfy tax obligations

Shares held after transactions 33,297 shares Directly owned Avalo Therapeutics common stock after March 28, 2026 transactions

RSU grant size 72,600 units Restricted stock units granted on August 13, 2024 with three annual vesting dates

RSU vesting dates March 28, 2025, 2026, 2027 One-third of 72,600 RSUs vesting on each date, subject to continued service

Key Terms

Restricted Stock Units, Exercise or conversion of derivative security, tax-withholding disposition

3 terms

Restricted Stock Units financial

"Restricted stock units convert into common stock on a one-for-one basis."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Exercise or conversion of derivative security financial

"transaction_code_description: Exercise or conversion of derivative security"

tax-withholding disposition financial

"transaction_action: tax-withholding disposition"

A tax-withholding disposition is an event or transaction—such as selling or transferring securities, exercising options, or receiving compensation—that triggers a requirement to hold back part of the payment and remit it to tax authorities. It matters to investors because it reduces the cash they receive immediately and can change the timing and amount of taxable income, like a cashier taking a portion of your sale proceeds to pay taxes before you get the rest.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Avalo Therapeutics (AVTX) report for its CFO?

Avalo Therapeutics’ CFO Christopher Ryan Sullivan reported RSU-based equity compensation. On March 28, 2026, 24,200 restricted stock units converted into 24,200 common shares, with a portion of those shares subsequently withheld to cover related tax obligations.

How many Avalo Therapeutics (AVTX) RSUs vested and converted for the CFO?

24,200 restricted stock units vested and converted into 24,200 shares of Avalo Therapeutics common stock. The conversion occurred on March 28, 2026 at a stated price of $0.00 per share, reflecting standard RSU settlement into equity rather than an open-market stock purchase.

How many Avalo Therapeutics (AVTX) shares were withheld for taxes in this Form 4?

8,241 shares of Avalo Therapeutics common stock were disposed of to satisfy tax obligations. These shares were valued at $13.89 per share for the tax-withholding transaction, representing a non-market sale mechanism rather than a discretionary open-market sale by the CFO.

How many Avalo Therapeutics (AVTX) shares does the CFO hold after these transactions?

Following the March 28, 2026 RSU conversion and tax-withholding disposition, the CFO directly holds 33,297 shares of Avalo Therapeutics common stock. This figure reflects the net position after issuing shares from RSUs and using some shares to cover associated tax liabilities.

What is the vesting schedule of the Avalo Therapeutics (AVTX) RSU grant mentioned?

On August 13, 2024, the CFO was granted 72,600 restricted stock units. These RSUs vest in three equal one-third installments on March 28, 2025, March 28, 2026, and March 28, 2027, contingent on the CFO’s continued service through each vesting date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/31/2026 - 04:10 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sullivan Christopher Ryan

(Last) (First) (Middle)

C/O AVALO THERAPEUTICS, INC.

1500 LIBERTY RIDGE DRIVE, SUITE 321

(Street)

WAYNE PENNSYLVANIA 19087

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Avalo Therapeutics, Inc. [ AVTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/28/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/28/2026		M		24,200	A	(1)	41,538	D
Common Stock	03/28/2026		F		8,241	D	$13.89	33,297	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	03/28/2026		M			24,200	(2)	(2)	Common Stock	24,200	$0	24,200	D

Explanation of Responses:

1. Restricted stock units convert into common stock on a one-for-one basis.

2. On August 13, 2024, the Reporting Person was granted 72,600 restricted stock units, vesting 1/3 on March 28, 2025, March 28, 2026, and March 28, 2027, subject to the Reporting Person's continued service on such vesting date.

	/s/ Christopher Sullivan, Attorney-in-Fact	03/31/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)